{"id":76647,"date":"2026-08-26T12:34:40","date_gmt":"2026-08-26T04:34:40","guid":{"rendered":"https:\/\/flcube.com\/?p=76647"},"modified":"2026-08-26T12:34:41","modified_gmt":"2026-08-26T04:34:41","slug":"ec-approves-gileads-trodelvy-plus-keytruda-for-first-line-pd-l1-positive-metastatic-tnbc-35-reduction-in-progression-risk","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76647","title":{"rendered":"EC Approves Gilead&#8217;s Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Gilead Sciences (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>)<\/strong> announced that the <strong>European Commission (EC)<\/strong> has granted <strong>marketing authorisation<\/strong> for the Trop\u20112 antibody\u2011drug conjugate <strong>Trodelvy (sacituzumab govitecan\u2011hziy)<\/strong> in combination with <strong>Merck &amp; Co., Inc. (MSD; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/MRK:NYSE\">NYSE: MRK<\/a>)<\/strong>&#8216;s PD\u20111 antibody <strong>Keytruda (pembrolizumab)<\/strong>. The approval covers adult patients with <strong>unresectable, locally advanced or metastatic triple\u2011negative breast cancer (TNBC)<\/strong> who have not received prior systemic therapy for metastatic disease and whose tumours express <strong>PD\u2011L1 with a combined positive score (CPS) \u226510<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>24 Aug 2026<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Trodelvy (sacituzumab govitecan\u2011hziy) + Keytruda (pembrolizumab)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line unresectable, locally advanced or metastatic PD\u2011L1\u2011positive (CPS \u226510) TNBC<\/td><\/tr><tr><td><strong>Supporting Data<\/strong><\/td><td>Phase 3 ASCENT\u201104\/KEYNOTE\u2011D19 study<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>Establishes an ADC + immunotherapy backbone as a new first\u2011line TNBC standard in Europe<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trodelvy:<\/strong> <strong>Trop\u20112\u2011directed antibody\u2011drug conjugate (ADC)<\/strong> delivering a topoisomerase I inhibitor payload to Trop\u20112\u2011expressing tumour cells<\/li>\n\n\n\n<li><strong>Keytruda:<\/strong> <strong>Anti\u2011PD\u20111 monoclonal antibody<\/strong> that restores T\u2011cell\u2011mediated anti\u2011tumour immunity<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> ADC\u2011mediated tumour killing combined with checkpoint blockade to deepen and prolong responses in first\u2011line metastatic TNBC<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> PD\u2011L1\u2011positive (CPS \u226510) patients with no prior systemic therapy for metastatic disease<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-ascent-04-keynote-d19-phase-3\" class=\"wp-block-heading\">Clinical Evidence \u2013 ASCENT\u201104\/KEYNOTE\u2011D19 (Phase 3)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Outcome (Trodelvy + Keytruda vs. SoC Chemotherapy + Keytruda)<\/th><\/tr><\/thead><tbody><tr><td><strong>Progression\u2011Free Survival (PFS)<\/strong><\/td><td>Highly statistically significant and clinically meaningful improvement<\/td><\/tr><tr><td><strong>Risk of Disease Progression or Death<\/strong><\/td><td><strong>35% reduction<\/strong> in PD\u2011L1\u2011positive metastatic TNBC<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>First\u2011line metastatic TNBC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The pivotal Phase 3 ASCENT\u201104\/KEYNOTE\u2011D19 study demonstrated that <strong>Trodelvy plus Keytruda<\/strong> delivered a highly statistically significant and clinically meaningful progression\u2011free survival benefit over the prior first\u2011line standard of care \u2014 chemotherapy combined with <strong>Keytruda<\/strong> \u2014 reinforcing the ADC + immunotherapy approach as a differentiated treatment paradigm in TNBC.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Standard of Care Shift:<\/strong> The approval establishes an ADC\u2011based combination as a new first\u2011line option in Europe, potentially displacing chemotherapy + Keytruda regimens in PD\u2011L1\u2011positive metastatic TNBC.<\/li>\n\n\n\n<li><strong>Strategic Alliance:<\/strong> The decision underscores the commercial value of the <strong>Gilead\u2013Merck (MSD)<\/strong> collaboration, pairing Gilead&#8217;s ADC platform with the world&#8217;s leading PD\u20111 franchise.<\/li>\n\n\n\n<li><strong>Commercial Upside:<\/strong> TNBC accounts for a meaningful share of breast cancers with historically limited durable treatment options; a first\u2011line combination label broadens Trodelvy&#8217;s addressable market in Europe.<\/li>\n\n\n\n<li><strong>Catalyst Watch:<\/strong> Label expansion and reimbursement uptake across EU member states, alongside ongoing ASCENT programme readouts, will be key near\u2011term drivers for GILD&#8217;s oncology franchise.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory adoption, clinical uptake, and commercial expectations for Trodelvy in combination with Keytruda. Actual results may differ due to risks including reimbursement decisions, competitive dynamics, and further regulatory actions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76650,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11,4908],"tags":[35,29,226,120,2675,176,1025,903,18,15],"class_list":["post-76647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-pic","tag-adc-xdc","tag-combination-therapy","tag-gilead-sciences","tag-merck","tag-merck-sharp-dohme","tag-msd","tag-nasdaq-gild","tag-nyse-mrk","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>EC Approves Gilead&#039;s Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for the Trop\u20112 antibody\u2011drug conjugate Trodelvy (sacituzumab govitecan\u2011hziy) in combination with Merck &amp; Co., Inc. (MSD; NYSE: MRK)&#039;s PD\u20111 antibody Keytruda (pembrolizumab). The approval covers adult patients with unresectable, locally advanced or metastatic triple\u2011negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumours express PD\u2011L1 with a combined positive score (CPS) \u226510.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76647\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EC Approves Gilead&#039;s Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for the Trop\u20112 antibody\u2011drug conjugate Trodelvy (sacituzumab govitecan\u2011hziy) in combination with Merck &amp; Co., Inc. (MSD; NYSE: MRK)&#039;s PD\u20111 antibody Keytruda (pembrolizumab). The approval covers adult patients with unresectable, locally advanced or metastatic triple\u2011negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumours express PD\u2011L1 with a combined positive score (CPS) \u226510.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76647\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T04:34:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-26T04:34:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"EC Approves Gilead&#8217;s Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk\",\"datePublished\":\"2026-08-26T04:34:40+00:00\",\"dateModified\":\"2026-08-26T04:34:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647\"},\"wordCount\":471,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2602.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Combination therapy\",\"Gilead Sciences\",\"Merck\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NASDAQ: GILD\",\"NYSE: MRK\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76647#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76647\",\"name\":\"EC Approves Gilead's Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2602.webp\",\"datePublished\":\"2026-08-26T04:34:40+00:00\",\"dateModified\":\"2026-08-26T04:34:41+00:00\",\"description\":\"Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for the Trop\u20112 antibody\u2011drug conjugate Trodelvy (sacituzumab govitecan\u2011hziy) in combination with Merck & Co., Inc. (MSD; NYSE: MRK)'s PD\u20111 antibody Keytruda (pembrolizumab). The approval covers adult patients with unresectable, locally advanced or metastatic triple\u2011negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumours express PD\u2011L1 with a combined positive score (CPS) \u226510.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76647\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2602.webp\",\"width\":1080,\"height\":608,\"caption\":\"EC Approves Gilead's Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76647#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EC Approves Gilead&#8217;s Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EC Approves Gilead's Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for the Trop\u20112 antibody\u2011drug conjugate Trodelvy (sacituzumab govitecan\u2011hziy) in combination with Merck & Co., Inc. (MSD; NYSE: MRK)'s PD\u20111 antibody Keytruda (pembrolizumab). The approval covers adult patients with unresectable, locally advanced or metastatic triple\u2011negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumours express PD\u2011L1 with a combined positive score (CPS) \u226510.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76647","og_locale":"en_US","og_type":"article","og_title":"EC Approves Gilead's Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk","og_description":"Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for the Trop\u20112 antibody\u2011drug conjugate Trodelvy (sacituzumab govitecan\u2011hziy) in combination with Merck & Co., Inc. (MSD; NYSE: MRK)'s PD\u20111 antibody Keytruda (pembrolizumab). The approval covers adult patients with unresectable, locally advanced or metastatic triple\u2011negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumours express PD\u2011L1 with a combined positive score (CPS) \u226510.","og_url":"https:\/\/flcube.com\/?p=76647","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-26T04:34:40+00:00","article_modified_time":"2026-08-26T04:34:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76647#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76647"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"EC Approves Gilead&#8217;s Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk","datePublished":"2026-08-26T04:34:40+00:00","dateModified":"2026-08-26T04:34:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76647"},"wordCount":471,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76647#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2602.webp","keywords":["ADC \/ XDC","Combination therapy","Gilead Sciences","Merck","Merck Sharp &amp; Dohme","MSD","NASDAQ: GILD","NYSE: MRK","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76647#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76647","url":"https:\/\/flcube.com\/?p=76647","name":"EC Approves Gilead's Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76647#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76647#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2602.webp","datePublished":"2026-08-26T04:34:40+00:00","dateModified":"2026-08-26T04:34:41+00:00","description":"Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for the Trop\u20112 antibody\u2011drug conjugate Trodelvy (sacituzumab govitecan\u2011hziy) in combination with Merck & Co., Inc. (MSD; NYSE: MRK)'s PD\u20111 antibody Keytruda (pembrolizumab). The approval covers adult patients with unresectable, locally advanced or metastatic triple\u2011negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumours express PD\u2011L1 with a combined positive score (CPS) \u226510.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76647#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76647"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76647#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2602.webp","width":1080,"height":608,"caption":"EC Approves Gilead's Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76647#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"EC Approves Gilead&#8217;s Trodelvy Plus Keytruda for First\u2011Line PD\u2011L1\u2011Positive Metastatic TNBC \u2013 35% Reduction in Progression Risk"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2602.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76647"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76647\/revisions"}],"predecessor-version":[{"id":76652,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76647\/revisions\/76652"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76650"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}